Patent Law

High Throughput Screening in Academia – Drug discovery initiatives at the University of Kansas By Dr P McDonald, Dr Roy, Byron Taylor, Ashleigh Price, Dr Sittampalam, Dr Scott Weir, Dr Chaguturu Academia has historically been involved in exploring the fundamental aspects of the disease targets and in developing tool molecules to better understand the genetic, […]

Automated Biobanking – The next big step for biorespositories By Dr John Comley As a significant proportion of the many newly established national, regional and disease-specific biobanks or biorespositories contemplate how they will enable enhanced sample integrity, tracking and audit trail, there has never been a more opportune time to consider biobanking automation. With the […]

India – Global pharmaceutical R&D powerhouse or contract research workshop? By Dr Matthew Howard In response to the ever-increasing costs of drug discovery and development, pharmaceutical industry leaders must constantly seek to increase productivity while simultaneously reducing costs and maintaining quality. Globalisation of drug discovery may provide such an opportunity, through the conduct of costly […]

The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity By Dr Kenneth C. Carter Conventional drug discovery and development is centred on a paradigm in which ‘validated’ targets are subjected to in vitro screens for the identification of new drug candidates. Molecular profiling using genomic approaches is becoming an […]

Stem Cell Patent Trends and The Promise of Stem Cell Therapies By Dr Gareth Williams Stem cell therapies hold great promise for future medical treatment, but in order to realise their potential there must be sufficient investment, private or public, in the technology. A key aspect of obtaining investment in any biotechnology field is the […]

Medicinal Chemistry: Progress through innovation By Dr Terry Hart Medicinal chemistry is a specialised science that has evolved to encompass a broad range of disciplines concerned with the identification, synthesis and development of drug-like compounds for therapeutic use. It needs a wide range of expertise, developed through years of training, dedication and learning from best […]

Ion Channel Drug Targets: Unlocking the potential By Dr Dayle S. Hogg, Dr Philip Boden, Dr Geoff Lawton and Dr Roland Z. Kozlowski A striking number of drugs targeting ion channels have reached blockbuster status, generating $ billion revenues. In spite of the historical success of ion channels as therapeutic targets and the considerable investment […]

The Timetable of Invention and it’s Relevance to Drug Discovery By Dr William Bains The most critical question to any investor in new technology should not be whether a technology will work. Technologies nearly always work in the end, providing they do not break fundamental laws of physics, and are not based on false discoveries […]

Outsourcing life-science innovations with university technology transfer By Dr Clifford M. Gross Universities and federally funded laboratories create thousands of new discoveries every year, the vast majority of which never see the light of day. We discuss various ways to harness those discoveries and potentially invigorate product pipelines. Invention is a sticky, unpredictable business. The […]

Redefining Drug Discovery Informatics By Bryan S. Koontz As the pharmaceutical industry changes in response to unprecedented challenges, information technology supporting the drug discovery process must evolve and be redefined in order to improve research productivity and success rates. Improvements to traditional computational chemistry applications will continue to provide incremental benefits, but drug discoverys productivity […]